Multiple Sclerosis (MS) is an autoimmune, inflammatory, and neurodegenerative disease characterized by neuroinflammation, demyelination and axonal degeneration of the central nervous system. Most of the new cases are detected in young adults (20-45 years old) and rare cases are detected before 20 years old. MS prevalence shows it is twice more common in women than in men. In most of the cases (around 90%), MS is characterized by alternating periods of relapse and remitting phases in which progression of the pathology is suddenly increased (a notably worsening of the patient is given during the episodes) or in a quiescent form, in which it seems that progression of the pathology is at least limited. Furthermore, it should be remarked that the disease is frequently underestimated because in most patients the first symptoms resolve spontaneously, and relapses are spaced on time (months/years).
To date, most of the therapies for Multiple Sclerosis are focused on only one of the aspects of the disease, the inflammatory process. Although, this is a very important aspect of MS it is not the only one. This makes it challenging to develop new effective treatments for this complex and multifactorial disease. On the other side, most of the patients that start with Relapsing Remitting MS (RRMS) forms evolve to Progressive MS (PMS), in which inflammation is less important and demyelination and nerve disfunction become the key players in the pathology. Therefore, new drugs and new tools of detection are required urgently in order to diminish the deleterious effects of the pathological processes that occur in MS.
In this Research Topic we welcome original research, brief research reports, systematic reviews, reviews, mini reviews and perspectives, and we would like to present the latest advances in MS therapies and diagnostic tools, including but not limited to :
1. new drug candidates that are been studied for different forms of MS(Relapsing Remitting MS, Primary Progressive MS and Secondary Progressive MS).
2. preclinical studies and reviews on data concerning those drugs in clinical trials.
3. new tools for better detection, discrimination, or those that could have a predictive value in the evolution of the disease. Therefore, the studies that could represent a significant value as predictors of the evolution or even anticipate new episodes or worsening are also welcomed.
Multiple Sclerosis (MS) is an autoimmune, inflammatory, and neurodegenerative disease characterized by neuroinflammation, demyelination and axonal degeneration of the central nervous system. Most of the new cases are detected in young adults (20-45 years old) and rare cases are detected before 20 years old. MS prevalence shows it is twice more common in women than in men. In most of the cases (around 90%), MS is characterized by alternating periods of relapse and remitting phases in which progression of the pathology is suddenly increased (a notably worsening of the patient is given during the episodes) or in a quiescent form, in which it seems that progression of the pathology is at least limited. Furthermore, it should be remarked that the disease is frequently underestimated because in most patients the first symptoms resolve spontaneously, and relapses are spaced on time (months/years).
To date, most of the therapies for Multiple Sclerosis are focused on only one of the aspects of the disease, the inflammatory process. Although, this is a very important aspect of MS it is not the only one. This makes it challenging to develop new effective treatments for this complex and multifactorial disease. On the other side, most of the patients that start with Relapsing Remitting MS (RRMS) forms evolve to Progressive MS (PMS), in which inflammation is less important and demyelination and nerve disfunction become the key players in the pathology. Therefore, new drugs and new tools of detection are required urgently in order to diminish the deleterious effects of the pathological processes that occur in MS.
In this Research Topic we welcome original research, brief research reports, systematic reviews, reviews, mini reviews and perspectives, and we would like to present the latest advances in MS therapies and diagnostic tools, including but not limited to :
1. new drug candidates that are been studied for different forms of MS(Relapsing Remitting MS, Primary Progressive MS and Secondary Progressive MS).
2. preclinical studies and reviews on data concerning those drugs in clinical trials.
3. new tools for better detection, discrimination, or those that could have a predictive value in the evolution of the disease. Therefore, the studies that could represent a significant value as predictors of the evolution or even anticipate new episodes or worsening are also welcomed.
